Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Novo Nordisk
Pharma
Novo to gradually phase out production of human insulin pens
As sales of Novo Nordisk’s GLP-1 drugs continue to soar, the Danish drugmaker is once again adjusting its insulin production priorities.
Fraiser Kansteiner
Nov 14, 2024 2:13pm
MSF calls on Lilly, Novo and Sanofi to charge $1 per insulin pen
Nov 11, 2024 10:59am
Novo, Lilly lost value in Q3 while BMS, Gilead and Sanofi surged
Nov 8, 2024 5:00am
Novo reports mixed sales on GLP-1 stalwarts Ozempic, Wegovy
Nov 6, 2024 2:34pm
Amid a new MASH market, ‘tremendous change’ is on the horizon
Nov 5, 2024 10:02am
Novo Nordisk's semaglutide delivers in phase 3 MASH study
Nov 1, 2024 10:38am
